# Downstream Versus Upstream Strategy for the Administration of P2Y12 Receptor Blockers

Study · id `cardio:ct-nct02618837` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02618837](<https://clinicaltrials.gov/study/NCT02618837>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02618837

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 2520 participants.

## Technical summary

Registry record NCT02618837. Randomized; no masking; primary purpose diagnostic. Start 2015-12-14 (actual); primary completion 2021-06 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose diagnostic
- Phase: Phase 4
- Enrolled: 2520 participants (planned count; ClinicalTrials.gov record NCT02618837, source copy `cardio:ctgov-nct02618837-2020-12-02`, retrieved 2026-10-26)
- Started: 2015-12-14 (actual) (ClinicalTrials.gov record NCT02618837, source copy `cardio:ctgov-nct02618837-2020-12-02`, retrieved 2026-10-26)
- Primary completion: 2021-06 (anticipated) (ClinicalTrials.gov record NCT02618837, source copy `cardio:ctgov-nct02618837-2020-12-02`, retrieved 2026-10-26)
- Completion: 2022-08 (anticipated) (ClinicalTrials.gov record NCT02618837, source copy `cardio:ctgov-nct02618837-2020-12-02`, retrieved 2026-10-26)
- Countries: Italy (ClinicalTrials.gov record NCT02618837, source copy `cardio:ctgov-nct02618837-2020-12-02`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02618837-2020-12-02`, retrieved 2026-10-26)

## The registry's words

- Brief title: Downstream Versus Upstream Strategy for the Administration of P2Y12 Receptor Blockers
- Acronym: DUBIUS
- Condition: Unstable Angina or Non ST Elevated Myocardial Infarction
- Intervention (Procedure): Downstream strategy
- Intervention (Procedure): Upstream strategy
- Lead sponsor: University of Padova
- Lead sponsor class: OTHER
- Collaborator: Azienda Ospedaliera di Padova
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: Non-ST-elevation heart attack (NSTEMI) (`cardio:nstemi`)
- Registry condition terms include this condition: Unstable angina (`cardio:unstable-angina`)
- Registry lists this organization as the lead sponsor: University of Padova (`cardio:org-university-of-padova`)

## Provenance

Content hash: bbd59e8609598a372627046668aa616d61fa2503aa8bc497b1d1399d7c72eebc
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
